- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03130361
Wearable Noninvasive Positive Pressure Ventilation Device in COPD (VITABREATH)
Evaluation of the Impact of a Wearable Noninvasive Positive Pressure Ventilation Device on Physical Activity and Quality of Life in Patients With COPD
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
In order to avoid the occurrence of uncomfortable dyspnea, patients with Chronic Obstructive Pulmonary Disease (COPD) are locked in a vicious circle of inactivity and social isolation which profoundly affects their quality of life and prognosis. A new wearable non invasive positive pressure ventilation device has been recently proposed; it can be used by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea- recovery time. The investigators hypothesize that this system, in reducing the inconvenience caused by dyspnea, would stimulate a more active lifestyle and improve quality of life. Their objective is to assess the impact of this device on physical activity and quality of life in patients with severe COPD, complaining of dyspnea.
In this open study with no control group, participants will use the device at their convenience, according to their needs in daily life and for 4 weeks.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Alès, Frankrike, 30100
- Dr Michèle Bognie Pneumology Office
-
Castelnau-le-Lez, Frankrike, 34000
- Clinique du Parc
-
Grenoble, Frankrike, 38043
- CHU Grenoble-Alpes
-
Lille, Frankrike, 59042
- Hôpital Privé La Louvière
-
Lunel, Frankrike, 34400
- Dr Christian PAILLARGUELO Pneumology Office
-
Nîmes, Frankrike, 30900
- CHU Caremeau
-
Toulouse, Frankrike, 31300
- Clinique Pasteur
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients with stable severe COPD (with FEV1 ≤50% predicted)
- Patients with mMRC score > ou = 2.
Exclusion Criteria:
- Exacerbate within a month prior.
- Using other non invasive ventilation device > 15h per day.
- Have musculoskeletal or neuromuscular problem affecting balance and walking.
- Have cognitive problem affecting comprehension of the different évaluations or questionnaires.
- Have recently participated in physical training or rehabilitation program (≤ 3 months).
- Medical contra-indication to NIV.
- Evolutionary pathologies (excluding COPD) may be life-threatening in the short term (1 year) (cancer, neuromuscular disease rapidly changing).
- Simultaneously enrolled in an other clinical trial.
- Not affiliated to social security.
- Person deprived of liberty, major protected by law.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Enhetens gjennomførbarhet
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Noninvasive ventilation
Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change of daily physical activity measured by actimetry
Tidsramme: Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
Change of number of steps by day and daily energy expenditure over the 8 week period
|
Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change of Baseline Dyspnea Index (BDI) score
Tidsramme: baseline and post use of the Vitabreath device at 4th weeks
|
The BDI represents importance and impact of dyspnea in daily life of COPD patients.
The BDI is one of dyspnea parameters (questionnaire).
Three dimension questions include; 1.effect of daily function on dyspnea, 2. effect of magnitude of task on dyspnea and 3. effect of magnitude off effort on dyspnea.
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Change of Modified Medical Research Council Questionnaire (mMRC) score
Tidsramme: baseline and post use of the Vitabreath device at 4th weeks
|
The mMRC is one of dyspnea parameters
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Change of Transition Dyspnea Index (TDI)
Tidsramme: baseline and post use of the Vitabreath device at 4th weeks
|
The TDI assesses change of dyspnea perception from the BDI in each dimensions.
Patient will rate score from -6 to +6 (positive score reflect improve of dyspnea and negative score reflect worse dyspnea).
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Subjective appréciation of the device
Tidsramme: post use of the Vitabreath device at 4th weeks
|
Patients will rate their appreciation of the device using 3 scale relatives to ease of use, helps recovery shortness of breath, helps to be more active in daily life
|
post use of the Vitabreath device at 4th weeks
|
|
Change of Visual Simplified Respiratory Questionnaire (VSRQ) score
Tidsramme: baseline and post use of the Vitabreath device at 4th weeks
|
The VRSQ represents health related quality of life of COPD patients
|
baseline and post use of the Vitabreath device at 4th weeks
|
|
Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT)score
Tidsramme: Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
The CAT represents health related quality of life of COPD patients
|
Continuously over a 8-week period (2 weeks before the use of the device, over the 4-week period usinf the device and 2 weeks after the use of the device
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Compliance to the device
Tidsramme: Every week over the 4-week period
|
During a weekly phone call, patients will indicate the daily duration and conditions of use of the device
|
Every week over the 4-week period
|
|
Number of acute exacerbation
Tidsramme: Up to 12 months before the date of inclusion
|
Exacerbation is defined as changing the respiratory status of the patient relative to the patient's usual state, which requires acute hospitalisation.
|
Up to 12 months before the date of inclusion
|
|
Weight
Tidsramme: baseline and post use of the Vitabreath device at 4th weeks
|
Patient will indicate their weight
|
baseline and post use of the Vitabreath device at 4th weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Jean-Louis PEPIN, Pr, Laboratoire du sommeil - Centre hospitalier Universitaire Michallon - 38043 GRENOBLE
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 2016-A01297-44
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Ikke-invasiv ventilasjon
-
Yonsei UniversityFullført
-
Algemeen Ziekenhuis Maria MiddelaresFullførtUtskifting av aortaklaffen | Mitralklaffkirurgi | Minimal invasiv hjertekirurgi | Minimal invasiv direkte koronararteriebypassBelgia
-
Universitätsklinikum Hamburg-EppendorfFullførtSerratus Anterior Plane Block | Minimal invasiv hjertekirurgi | Minimal invasiv hjertekirurgi MitralklaffkirurgiTyskland
-
Fisher and Paykel HealthcareHar ikke rekruttert ennå
-
Wenjin YinAktiv, ikke rekrutterendeBrystkreft InvasivKina
-
Hospital H+ QueretaroFullførtInvasiv aspergilloseMexico
-
Wenjin YinAktiv, ikke rekrutterendeBrystkreft InvasivKina
-
CSPC Ouyi Pharmaceutical Co., Ltd.FullførtInvasiv soppsyndromKina
-
Wenjin YinAktiv, ikke rekrutterende
-
CSPC Ouyi Pharmaceutical Co., Ltd.FullførtInvasiv aspergillose | Invasiv candidiasisKina
Kliniske studier på Non-Invasive Ventilation
-
Fundació Institut de Recerca de l'Hospital de la...Spanish Respiratory SocietyFullførtFedme HypoventilasjonssyndromSpania
-
Natera, Inc.RekrutteringEnkelt gen niptForente stater
-
University of ChicagoFullførtSjokk | Akutt lungesviktsyndrom | Ventilasjonssvikt | Kardiogent lungeødemForente stater
-
Emory UniversityFullførtRask sekvensintubasjonForente stater
-
Assiut UniversityRekrutteringSamfunnservervet lungebetennelse | Samfunnservervede infeksjonerEgypt
-
University of SydneyRoyal Prince Alfred Hospital, Sydney, AustraliaAvsluttet
-
Oregon Health and Science University4DMedicalPåmelding etter invitasjonLungesykdommer | KOLS | Luftveissykdom | DyspnéForente stater
-
Assiut UniversityRekrutteringGuillain-Barre syndromEgypt
-
University of Wisconsin, MadisonAvsluttetAkutt lungeskade | Adult Respiratory Distress SyndromeForente stater